- Home
- Publications
- Publication Search
- Publication Details
Title
An overview of the mTOR pathway as a target in cancer therapy
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 16, Issue 5, Pages 481-489
Publisher
Informa Healthcare
Online
2012-04-12
DOI
10.1517/14728222.2012.677439
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting mTOR for the treatment of AML. New agents and new directions.
- (2015) Jessica K. Altman et al. Oncotarget
- Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
- (2011) M. Gupta et al. BLOOD
- A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas
- (2011) Scott Okuno et al. CANCER
- Activation of mTORC2 by Association with the Ribosome
- (2011) Vittoria Zinzalla et al. CELL
- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
- (2011) Paige Yellen et al. CELL CYCLE
- Impact ofBCR-ABLmutations on patients with chronic myeloid leukemia
- (2011) Andreas Hochhaus et al. CELL CYCLE
- Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors
- (2011) J. K. Altman et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: BCR-ABL
- (2011) D. Cilloni et al. CLINICAL CANCER RESEARCH
- mTOR signaling in disease
- (2011) Eva Dazert et al. CURRENT OPINION IN CELL BIOLOGY
- Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
- (2011) Nushmia Z. Khokhar et al. CURRENT OPINION IN ONCOLOGY
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
- (2011) Jorge J Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The role of LKB1 in lung cancer
- (2011) Montse Sanchez-Cespedes Familial Cancer
- Future Directions in Renal Cell Carcinoma: 2011 and Beyond
- (2011) Daniel C. Cho et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- mTOR Inhibitors in Advanced Renal Cell Carcinoma
- (2011) Martin H. Voss et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
- (2011) Jorge Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR–ABL
- (2011) Amanda J. Redig et al. LEUKEMIA & LYMPHOMA
- New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
- (2011) Amber Fullmer et al. LEUKEMIA & LYMPHOMA
- Mechanisms of resistance to BCR–ABL kinase inhibitors
- (2011) Joana M. Diamond et al. LEUKEMIA & LYMPHOMA
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- New molecular targets in mantle cell lymphoma
- (2011) Samir Parekh et al. SEMINARS IN CANCER BIOLOGY
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells
- (2010) Eliza Vakana et al. Autophagy
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
- (2010) D Bixby et al. LEUKEMIA
- mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells
- (2010) Weina Chen et al. Molecular Cancer
- Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
- (2010) Matthew R Janes et al. NATURE MEDICINE
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells
- (2010) Nathalie Carayol et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
- (2009) F. Chiarini et al. CANCER RESEARCH
- An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
- (2009) Carson C. Thoreen et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
- (2009) Edoardo Missiaglia et al. JOURNAL OF CLINICAL ONCOLOGY
- The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
- (2008) Amancio Carnero et al. CURRENT CANCER DRUG TARGETS
- Exploiting the mammalian target of rapamycin pathway in hematologic malignancies
- (2008) Jessica K Altman et al. CURRENT OPINION IN HEMATOLOGY
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
- (2008) Alfredo Toschi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
- (2008) Michael G. Kharas et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
- (2008) K Kojima et al. LEUKEMIA
- PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML
- (2008) S Park et al. LEUKEMIA
- Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome
- (2008) Fernando Callera et al. LEUKEMIA RESEARCH
- Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin
- (2008) A. Toschi et al. MOLECULAR AND CELLULAR BIOLOGY
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started